Form 4: Travere Therapeutics SVP Sells Shares Under 10b5-1 Plan

Travere Therapeutics' SVP, Chief Accounting Officer Sandra Calvin sold 7,402 shares of common stock for $40 per share, reducing her direct beneficial ownership to 38,233 shares.

Summary

• Sandra Calvin, SVP and Chief Accounting Officer of Travere Therapeutics, Inc. (TVTX), reported a sale of common stock.
• The transaction involved the disposition of 7,402 shares of Travere Therapeutics common stock.
• The shares were sold at a price of $40 per share.
• The sale occurred on December 24, 2025.
• This transaction was executed pursuant to a Rule 10b5-1(c) written plan, which was adopted on June 10, 2025.
• Following this transaction, Sandra Calvin directly beneficially owns 38,233 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a pre-planned sale under a 10b5-1 plan, which is a routine event for executives and generally considered neutral as it does not necessarily reflect a change in management's outlook on the company's prospects.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: A routine, pre-planned insider sale typically has minimal direct impact on shareholders, as it is not indicative of new material information.

Key Dates

Keywords

Travere Therapeutics, TVTX, Insider Trading, Form 4, Stock Sale, Executive Compensation, 10b5-1 Plan, Sandra Calvin